Cansino Biologics Stock Today
| CASBF Stock | USD 3.90 0.00 0.00% |
Performance15 of 100
| Odds Of DistressLess than 17
|
CanSino Biologics is trading at 3.90 as of the 21st of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 3.9. CanSino Biologics has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for CanSino Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. The company has 114.78 M outstanding shares. More on CanSino Biologics
Moving against CanSino Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
CanSino Pink Sheet Highlights
| Thematic Ideas | (View all Themes) |
| Business Concentration | Soft Drinks, Beers, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
CanSino Biologics [CASBF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CanSino Biologics's market, we take the total number of its shares issued and multiply it by CanSino Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. CanSino Biologics classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 114.78 M outstanding shares.
CanSino Biologics has accumulated about 7 B in cash with 2.05 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check CanSino Biologics Probability Of Bankruptcy
Ownership AllocationCanSino Biologics holds a total of 114.78 Million outstanding shares. CanSino Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CanSino Ownership Details
CanSino Biologics Risk Profiles
| Mean Deviation | 2.82 | |||
| Standard Deviation | 6.81 | |||
| Variance | 46.36 | |||
| Risk Adjusted Performance | 0.1136 |
CanSino Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in CanSino Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
CanSino Biologics Corporate Management
| Yonghui Wu | VP Marketing | Profile | |
| Xuefeng Yu | Chairman, CoFounder | Profile | |
| Tao Zhu | Ex CoFounder | Profile | |
| Chunlin Xin | Director Department | Profile | |
| Xi Luo | Chief Officer | Profile | |
| FCS FCIS | Joint Sec | Profile | |
| Dongxu MBA | Exec CoFounder | Profile |
Other Information on Investing in CanSino Pink Sheet
CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.